SUP Lidocaine — Competitive Intelligence Brief

SUP Lidocaine (SUP Lidocaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain management / Anesthesia.

marketed Local anesthetic Voltage-gated sodium channels Pain management / Anesthesia Small molecule

Target snapshot

SUP Lidocaine (SUP Lidocaine) — University of Michigan. SUP Lidocaine is a topical formulation of lidocaine, a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SUP Lidocaine TARGET	SUP Lidocaine	University of Michigan	marketed	Local anesthetic	Voltage-gated sodium channels
intravenous saline plus perineural bupivacaine	intravenous saline plus perineural bupivacaine	Sherif Mohamed Abd el moneim Soaida, MD	marketed	Local anesthetic with supportive fluid therapy	Voltage-gated sodium channels (Nav)
Depofoam bupivacaine	Depofoam bupivacaine	The Cleveland Clinic	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Brand lamotrigine	Brand lamotrigine	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine generic "B"	Lamotrigine generic "B"	University of Cincinnati	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Hyperbaric Bupivicaine	Hyperbaric Bupivicaine	University of Witwatersrand, South Africa	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Lidocaïne 2%	Lidocaïne 2%	University of Liege	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class